- ClearPoint Neuro ( NASDAQ: CLPT ) on Monday announced the enrollment of the first patient in a Glioblastoma clinical trial using the ClearPoint Prism Neuro Laser Therapy System.
- The Laser Thermal Ablation of Brain Lesions study is a single-arm trial evaluating the safety and feasibility of using the minimally invasive MR-guided laser therapy system to ablate tumor in up to five Glioblastoma patients.
- ClearPoint Neuro has exclusive global rights to commercialize the ClearPoint Prism Neuro Laser Therapy System.
For further details see:
ClearPoint Neuro enrolls first patient in glioblastoma trial using clearpoint prism neuro laser therapy system